Parma, Italy

David Ganderton

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 119(Granted Patents)


Location History:

  • Devon, GB (2004 - 2006)
  • Parma, IT (2005 - 2012)

Company Filing History:


Years Active: 2004-2012

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: David Ganderton: Pioneering Inventor in Pharmaceutical Formulations

Introduction: David Ganderton, a prominent inventor based in Parma, Italy, has made significant contributions in the field of pharmaceutical formulations. With a total of 11 patents to his name, Ganderton is recognized for his innovative approach to developing cutting-edge medical solutions.

Latest Patents: Among his notable inventions are the "Formoterol superfine formulation" and "Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide" patents. These patents showcase Ganderton's expertise in creating advanced formulations for inhalation therapies, utilizing unique container designs and specific internal surface compositions.

Career Highlights: David Ganderton has established himself as a key figure at Chiesi Farmaceutici S.p.A., a renowned pharmaceutical company. His groundbreaking work has led to the successful development of novel medications that have improved the lives of many patients worldwide.

Collaborations: Throughout his career, Ganderton has collaborated with esteemed professionals such as David Andrew Lewis and Gaetano Brambilla. Together, they have shared insights, exchanged ideas, and worked towards achieving common goals in the pharmaceutical industry.

Conclusion: In conclusion, David Ganderton stands as a testament to the power of innovation and creativity in driving positive change within the realm of pharmaceutical formulations. His dedication to pushing boundaries and his commitment to excellence have solidified his legacy as a pioneering inventor in the field of medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…